Dan Burgess, Chairman of the Nabriva Board of Directors commented, “We are excited to welcome Mark back to the Nabriva Board and are absolutely delighted to welcome Lisa to the Nabriva Board. Mark’s extensive experience in the industry from both a scientific and executive level brings a wealth of experience and knowledge to the Board. Likewise, the addition of Lisa’s extensive experience in human resources and executive management will be an invaluable asset to the organization. Mr. Burgess added, “On behalf of the entire Board, I would also like to thank Dr. Talbot for his efforts, input and many contributions to Nabriva over the past 12 years.”
Dr. Corrigan is a highly successful pharmaceutical executive with 30 years of industry experience, including roles as CEO, Global R&D Lead and serving on the Boards of other biotech companies. Dr. Corrigan currently serves as Chairman of the Board of Exacis Therapeutics, as well as Co-Founder and Board Member of Tremeau Pharmaceuticals, Inc.
Dr. Corrigan holds a Bachelor of Science from the University of Virginia, as well as an MD from the University of Virginia School of Medicine.
Ms. Dalton is a highly experienced pharmaceutical and biotechnology executive with over 25 years in the industry. Currently Ms. Dalton serves as Chief People Officer at Spark Therapeutics, Inc. (Roche Holdings AG). Prior to joining Spark, Ms. Dalton spent 10 years at Shire plc (now Takeda) in various leadership roles within the Human Resources function.
Ms. Dalton holds a Bachelor of Arts degree in Psychology from The Pennsylvania State University and a Master of Business Administration in Organizational Behavior Studies from Rutgers University.
About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.
Any statements in this press release about future expectations, plans and prospects for Nabriva Therapeutics, including but not limited to statements about the potential benefits to Nabriva Therapeutics under its sales promotion and distribution agreement with the subsidiaries of Merck & Co. Inc., Kenilworth, NJ, USA the potential benefits to patients of SIVEXTRO and XENLETA, the market opportunity for SIVEXTRO and XENLETA, the availability of SIVEXTRO through major U.S. specialty wholesalers, the impact on Nabriva Therapeutics’ reported revenue from anticipated sales of SIVEXTRO, the sufficiency of its cash resources and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: Nabriva Therapeutic’s ability to maintain the conditions under the distribution agreement to exclusively distribute and promote SIVEXTRO, including its ability to maintain a commercial infrastructure sufficient to promote and distribute SIVEXTRO, the extent of business interruptions resulting from the infection causing the COVID-19 outbreak or similar public health crises, the ability to retain and hire key personnel, the availability of adequate additional financing on acceptable terms or at all and such other important factors as are set forth in Nabriva Therapeutics’ annual and quarterly reports and other filings on file with the SEC. In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics’ views as of the date of this press release. Nabriva Therapeutics anticipates that subsequent events and developments may cause its views to change. However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Nabriva Therapeutics’ views as of any date subsequent to the date of this press release.